Citigroup Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its price target increased by research analysts at Citigroup from $140.00 to $156.00 in a note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective would suggest a potential upside of 11.65% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC boosted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Scotiabank began coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $135.36.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $139.72 on Tuesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a 50-day moving average of $124.76 and a 200-day moving average of $119.24. Gilead Sciences has a one year low of $93.37 and a one year high of $141.71. The company has a market cap of $173.35 billion, a P/E ratio of 21.66, a P/E/G ratio of 0.74 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the firm posted $2.02 EPS. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the insider directly owned 103,221 shares of the company’s stock, valued at $12,831,402.51. This trade represents a 2.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 247,397 shares of company stock valued at $31,986,612. 0.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Gilead Sciences during the second quarter worth about $2,150,268,000. Ameriprise Financial Inc. lifted its position in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after buying an additional 4,113,999 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after buying an additional 2,169,266 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Phase‑3 Trodelvy combo beat Keytruda + chemo in a pivotal study, sparking a sharp rally and renewed bullish debate about Gilead’s oncology upside. Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial
• Positive Sentiment: Multiple analyst upgrades/price‑target raises (Citigroup to $156, Truist, BMO, UBS commentary) are reinforcing buy-side momentum and likely supporting higher valuations in the near term. Citigroup adjusts price target on Gilead Sciences to 156 from 140; maintains buy rating
• Neutral Sentiment: Gilead will report Q4 & full‑year 2025 results on Feb 10 — a clear near‑term catalyst that could amplify either the positive trial reaction or reveal operational headwinds. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
• Neutral Sentiment: News aggregator and investor‑attention pieces (Zacks, sector writeups) are boosting visibility but are not new fundamental information. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Short‑interest data in the feed shows zero shares/NaN (likely a reporting artifact) — not a reliable signal for positioning or squeeze risk today.
• Negative Sentiment: CEO Daniel O’Day sold 115,640 shares (~$15.6M) in late January, reducing his holding ~17% — a notable insider sale that market participants may view as a short‑term negative or liquidity event. SEC filing: Form 4 — Daniel Patrick O’day sale

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.